Market Place
Sourcing Support
ONCOTELIC CLINICAL PRESENTATIONS AT SITC 2024
06 Nov 2024 //
GLOBENEWSWIRE
ONCOTELIC PUBLISHED ITS FOURTH PUBLICATION ON TGFB2 THERAPEUTICS
28 Oct 2024 //
#N/A
ONCOTELIC Presents at Precision in Drug Discovery Summit
23 Oct 2024 //
GLOBENEWSWIRE
Scott Myers To Present At 2nd Global Summit On Artificial Intelligence
29 Jul 2024 //
GLOBENEWSWIRE
ONCOTELIC TO PRESENT AT THE 20TH ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERY
11 Jun 2024 //
GLOBENEWSWIRE
ONCOTELIC TO PARTICIPATE AT THE BIO INTERNATIONAL 2024 MEETING
30 May 2024 //
GLOBENEWSWIRE
Oncotelic to Participate at The Asco 2024 Meeting
20 May 2024 //
GLOBENEWSWIRE
Oncotelic Presenting at Biopharma Nexus Conference San Diego 2024
08 May 2024 //
GLOBENEWSWIRE
4P-Pharma raises €15M; Oncotelic Therapeutics sells rights to cancer assets
29 Apr 2024 //
ENDPTS
Oncotelic to Sell Necroptosis Assets to Mosaic ImmunoEngineering
29 Apr 2024 //
GLOBENEWSWIRE
Linkage of Cancer and Lupus in Gliomas Patients
25 Mar 2024 //
GLOBENEWSWIRE
Invitation to Participate in STOP-PC Clinical Trial
04 Mar 2024 //
GLOBENEWSWIRE
Oncotelic Announces Linkage of TGFB2 and IFNGR2 in Pediatric DMG Patients
16 Jan 2024 //
GLOBENEWSWIRE
Oncotelic Therapeutics Announces Opening of GMP Manufacturing Plant
18 Dec 2023 //
GLOBENEWSWIRE
Oncotelic Therapeutics Announces CEO To Discuss Proprietary AI Technology
28 Nov 2023 //
GLOBENEWSWIRE
Oncotelic Reports Q3 2023 Compared to Q3 2022 Financial Results
15 Nov 2023 //
GLOBENEWSWIRE
Oncotelic Awarded Top Cancer Immunotherapy Solutions Provider 2023
25 Aug 2023 //
GLOBENEWSWIRE
Sapu and Cromos initiating P201 – A Registrational trial for OT-101
23 Aug 2023 //
GLOBENEWSWIRE
Oncotelic Launches PR Chatbot
12 Jun 2023 //
GLOBENEWSWIRE
Oncotelic Participating at 2023 BIO International Convention
16 May 2023 //
GLOBENEWSWIRE
Oncotelic Launches PDAO SEC Chatbot
24 Apr 2023 //
GLOBENEWSWIRE
Oncotelic Therapeutics and Vectara Announce Strategic Partnership
19 Apr 2023 //
GLOBENEWSWIRE
ONCOTELIC PROVIDES YE 2022FYR COMPARED TO YE 2021 PRODUCT DEVELOPMENT
17 Apr 2023 //
GLOBENEWSWIRE
Oncotelic Announces Release of Pet2DAO Tokens (PDAO)
03 Apr 2023 //
GLOBENEWSWIRE
Oncotelic Announces Pet2DAO Website is Live
20 Mar 2023 //
GLOBENEWSWIRE
Intra-Tumor TGF-?2 Predicts Poor Survival in Pediatric Cancer
13 Mar 2023 //
GLOBENEWSWIRE
Oncotelic Initiates Clinical Trials Evaluating OT-101
25 Jan 2023 //
GLOBENEWSWIRE
Oncotelic Announces the launch of PDAO token
17 Jan 2023 //
GLOBENEWSWIRE
Oncotelic Presents Data of Confirming TGF-?2 as appropriate target for gliomas
19 Dec 2022 //
GLOBENEWSWIRE
Oncotelic Publishes SNO 27th Annual Meeting Presentation Materials
30 Nov 2022 //
GLOBENEWSWIRE
Oncotelic Reports Q3 2022 Compared to Q3 2021 Financial Results
21 Nov 2022 //
GLOBENEWSWIRE
Oncotelic Initiates Clinical Trials Evaluating OT-101 against Pediatric Gliomas
08 Nov 2022 //
BIOSPACE
Oncotelic receives BARDA contract for long Covid-19 therapy development
13 Oct 2022 //
PHARMACEUTICAL-TECHNOLOGY
Oncotelic Awarded BARDA Funding for Development of OT-101 for long COVID
12 Oct 2022 //
GLOBENEWSWIRE
Oncotelic Presenting Data for OT101 Against Pancreatic Cancer (PDAC)
28 Sep 2022 //
GLOBENEWSWIRE
Oncotelic Presenting Data for OT101 Against Diffuse Intrinsic Pontine Glioma
14 Sep 2022 //
GLOBENEWSWIRE
Oncotelic Reports Q2 2022 Compared To Q2 2021 Financial Results
22 Aug 2022 //
GLOBENEWSWIRE
Oncotelic Participating at Biotechgate Digital Partnering
17 Aug 2022 //
GLOBENEWSWIRE
Oncotelic to Present on P001- OT-101 PI/II Trial in Pancreatic Cancer
12 Jul 2022 //
GLOBENEWSWIRE
Oncotelic Provides Update on OT-101 at the 2022 BIO International Convention
15 Jun 2022 //
GLOBENEWSWIRE
ONCOTELIC PROVIDES Q1 2022 FINANCIAL RESULTS COMPARED TO Q1 2021
23 May 2022 //
GLOBENEWSWIRE
ONCOTELIC ANNOUNCES US PATENT GRANT FOR CA4P AND OXI4503 COMBINATION
11 May 2022 //
GLOBENEWSWIRE
Oncotelic Appoints Seymour Fein M.D. as Chief Regulatory Officer
04 May 2022 //
GLOBENEWSWIRE
Oncotelic Appoints Fatih Uckun, M.D., Ph.D., as Chief Medical Officer
03 May 2022 //
GLOBENEWSWIRE
Oncotelic Provides YE 2021 Financial Results Compared To YE 2020
18 Apr 2022 //
GLOBENEWSWIRE
Oncotelic and Dragon Overseas Capital Ltd Completed Joint Venture Transaction
04 Apr 2022 //
GLOBENEWSWIRE
Oncotelic to Present New Studies on its TGF-β Program at the AACR (AACR) 2022
10 Mar 2022 //
GLOBENEWSWIRE
Oncotelic Presenting at MedInvest Pharmaceutical and Biotechnology Conference
24 Feb 2022 //
GLOBENEWSWIRE
Oncotelic Presenting at BiotechGate Digital Partnering
19 Jan 2022 //
GLOBENEWSWIRE
Oncotelic’s Dr. Anthony Maida to Present at 2nd Annual TGF-? for Immuno-Oncology
14 Dec 2021 //
GLOBENEWSWIRE
Oncotelic’s OT-101 meets safety and efficacy goals in Covid-19 trial
23 Nov 2021 //
PHARMACEUTICAL-TECHNOLOGY
ONCOTELIC ANNOUNCES POSITIVE TOPLINE DATA FOR OT-101 C001 COVID STUDY
23 Nov 2021 //
GLOBENEWSWIRE
Oncotelic Announces Successful Completion of the Safety Evaluation
16 Nov 2021 //
GLOBENEWSWIRE
ONCOTELIC ANNOUNCES UPDATE ON THE OT-101 CLINICAL PROGRAMS INCLUDING C001
20 Oct 2021 //
GLOBENEWSWIRE
ONCOTELIC ACQUIRES FAST TO MARKET LATE-STAGE DRUG CANDIDATE FOR PARKINSON
04 Oct 2021 //
GLOBENEWSWIRE
ONCOTELIC ACQUIRES FAST TO MARKET LATE-STAGE DRUG CANDIDATE FOR PARKINSON
04 Oct 2021 //
GLOBENEWSWIRE
